CHRS
Coherus Biosciences Inc

5,020
Loading...
Loading...
News
all
press releases
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and +1.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·3mo ago
News Placeholder
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Zacks·4mo ago
News Placeholder
Coherus Biosciences price target lowered by $2 at H.C. Wainwright, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Commit To Purchase Coherus BioSciences At $2, Earn 42.6% Annualized Using Options
Investors eyeing a purchase of Coherus BioSciences Inc (CHRS) shares, but cautious about paying the going market price of 2.37/share, might benefit from considering selling puts among the...
Stock Options Channel·1y ago
News Placeholder
Q4 2023 Coherus BioSciences Inc Earnings Call Transcript
Related Stocks: NAS:CHRS...
GuruFocus·1y ago
News Placeholder
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
Company Focuses on Oncology and Launches New Products Amidst RestructuringRelated Stocks: CHRS...
GuruFocus·1y ago
News Placeholder
Coherus Biosciences reports Q4 EPS (62c), consensus (12c)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 UDENYCA net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 CIMERLI net...
Globe Newswire·1y ago

Latest CHRS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.